Literature DB >> 4790572

Sisomicin: evaluation in vitro and comparison with gentamicin and tobramycin.

C C Crowe, E Sanders.   

Abstract

Sisomicin is a new antibiotic produced by Micromonospora inyoensis. The in vitro activities of sisomicin, gentamicin, and tobramycin, three similar aminoglycosides, were determined against 228 clinical isolates representing 10 genera of common pathogens. No difference was noted in the activities of these antimicrobial agents when assayed by a standard broth dilution technique against Klebsiella, Enterobacter, Escherichia, Salmonella, Citrobacter, enterococci, or Staphylococcus aureus. Sisomicin was significantly more active than tobramycin against Serratia and indole-positive Proteus strains. Sisomicin was significantly more active than gentamicin against indole-negative Proteus strains and slightly more active against indole-positive Proteus strains. Tobramycin was more active than sisomicin or gentamicin against Pseudomonas and indole-negative Proteus strains. Gram-negative bacilli resistant to one of the three antimicrobial agents were not necessarily resistant to either of the other two. Activity of sisomicin was independent of the susceptibility or resistance of these isolates to nine other antimicrobial agents as assayed by the Bauer-Kirby technique. The presence of 50% human serum did not antagonize the in vitro activity of sisomicin against gram-negative isolates. Because sisomicin showed certain advantages over gentamicin or tobramycin in vitro, further investigation of this new antimicrobial agent is warranted.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4790572      PMCID: PMC444355          DOI: 10.1128/AAC.3.1.24

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Numerical diagnostic key for the identification of Enterobacteriaceae.

Authors:  H Baer; L Washington
Journal:  Appl Microbiol       Date:  1972-01

2.  Status of kanamycin in the treatment of surgical infections.

Authors:  A M Rutenburg
Journal:  Ann N Y Acad Sci       Date:  1966-06-14       Impact factor: 5.691

Review 3.  Absorption, distribution, excretion and fate of kanamycin.

Authors:  C M Kunin
Journal:  Ann N Y Acad Sci       Date:  1966-06-14       Impact factor: 5.691

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Preliminary studies with nebramycin factor 6.

Authors:  H R Black; R S Griffith
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

6.  Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic.

Authors:  M J Weinstein; J A Marquez; R T Testa; G H Wagman; E M Oden; J A Waitz
Journal:  J Antibiot (Tokyo)       Date:  1970-11       Impact factor: 2.649

7.  Cross-resistance of Pseudomonas to gentamicin and tobramycin.

Authors:  J L Brusch; M Barza; M G Bergeron; L Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1972-03       Impact factor: 5.191

8.  Antibiotic 6640. 3. Biological studies with antibiotic 6640, a new broad-spectrum aminoglycoside antibiotic.

Authors:  J A Waitz; E L Moss; E M Oden; M J Weinstein
Journal:  J Antibiot (Tokyo)       Date:  1970-11       Impact factor: 2.649

9.  Laboratory and clinical evaluation of carbenicillin (carboxybenzyl penicillin).

Authors:  F Silverblatt; M Turck
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

10.  Influence of serum and calcium on the bactericidal activity of gentamicin and carbenicillin on Pseudomonas aeruginosa.

Authors:  S D Davis; A Iannetta
Journal:  Appl Microbiol       Date:  1972-04
View more
  22 in total

1.  Antistaphylococcal activity of sisomicin and four other aminoglycosides against strains sensitive and resistant to methicillin.

Authors:  E Yourassowsky; E Schoutens; M P Vanderlinden
Journal:  Infection       Date:  1975       Impact factor: 3.553

2.  Synergy of penicillin-netilmicin combinations against enterococci including strains highly resistant to streptomycin or kanamycin.

Authors:  C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

3.  Efficacy and pharmacokinetics of tobramycin in patients with chronic urinary tract infections and various degrees of renal impairment.

Authors:  S R Westenfelder; G Welling; P O Madsen
Journal:  Infection       Date:  1974       Impact factor: 3.553

4.  Rosamicin: evaluation in vitro and comparison with erythromycin and lincomycin.

Authors:  C C Crowe; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

Review 5.  Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

Authors:  P Noone
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Sisomicin versus netilmicin: in vitro susceptibility testing.

Authors:  D J Flournoy
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

7.  In vitro comparison of gentamicin, tobramycin, sisomicin, and netilmicin.

Authors:  K N Brown; J Benedictson; S Swanby
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

8.  Characterization and identification of a novel marine Streptomyces sp. produced antibacterial substance.

Authors:  Yingjian Lu; Xin Dong; Shu Liu; Xiaomei Bie
Journal:  Mar Biotechnol (NY)       Date:  2009-03-11       Impact factor: 3.619

9.  [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].

Authors:  H H Schassan
Journal:  Infection       Date:  1976       Impact factor: 3.553

10.  Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection.

Authors:  S Roth; K Naber; M Scheer; G Gruenwaldt; H Lange
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.